Abstract
The objective of this open parallel-group pilot study wa to assess the safety and efficacy of terbinafine (Lamisil®), a new allylamine antifungal agent, compared with griseofulvin in the treatment of tinea imbricata. The study was carried out in patients living in remote villages in the Central Kalimantan province of Indonesia. Patients entering the study had tinea imbricata due to Trichophyton concentricum, confirmed by mycological as well as clinical evaluation. A total of 55 patients were given either terbinafine at 250 mg once daily (n = 30) or griseofulvin at 500 mg once daily (n = 25) for 6 weeks, after which follow-ups were made at 2 and 5 months to assess relapse. Clinical and mycological examinations were carried out before and after treatment, and during follow-ups.All 30 patients taking terbinafine were evaluable and were completely (clinically and mycologically) cured (100%). In contrast, of the 23/25 evaluable patients taking griseofulvin, 16 (70%) were completely cured and 7 (30%) showed no ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
